Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015 (2015), Article ID 564934, 15 pages
http://dx.doi.org/10.1155/2015/564934
Review Article

Osteoprotegerin in Cardiometabolic Disorders

1Department of Clinical Chemistry, Clínica Universidad de Navarra, Avenida Pío XII 36, 31008 Pamplona, Spain
2Department of Cardiovascular Science, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK

Received 3 December 2014; Revised 20 April 2015; Accepted 20 April 2015

Academic Editor: Giorgio Iervasi

Copyright © 2015 C. Pérez de Ciriza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. S. Simonet, D. L. Lacey, C. R. Dunstan et al., “Osteoprotegerin: a novel secreted protein involved in the regulation of bone density,” Cell, vol. 89, no. 2, pp. 309–319, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Tsuda, M. Goto, S.-I. Mochizuki et al., “Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis,” Biochemical and Biophysical Research Communications, vol. 234, no. 1, pp. 137–142, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Yasuda, N. Shima, N. Nakagawa et al., “Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro,” Endocrinology, vol. 139, no. 3, pp. 1329–1337, 1998. View at Google Scholar
  4. S. M. Venuraju, A. Yerramasu, R. Corder, and A. Lahiri, “Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity,” Journal of the American College of Cardiology, vol. 55, no. 19, pp. 2049–2061, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. I. Silva and J. C. Branco, “Rank/RANKL/OPG: literature review,” Acta Reumatologica Portuguesa, vol. 36, no. 3, pp. 209–218, 2011. View at Google Scholar · View at Scopus
  6. “Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption,” Journal of Bone and Mineral Research, vol. 15, no. 12, pp. 2293–2296, 2000. View at Publisher · View at Google Scholar
  7. M. J. Hilton, L. Gutierrez, L. Zhang et al., “An integrated physical map of 8q22-q24: use in positional cloning and deletion analysis of Langer-Giedion syndrome,” Genomics, vol. 71, no. 2, pp. 192–199, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Montagnana, G. Lippi, E. Danese, and G. C. Guidi, “The role of osteoprotegerin in cardiovascular disease,” Annals of Medicine, vol. 45, no. 3, pp. 254–264, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Theoleyre, Y. Wittrant, S. K. Tat, Y. Fortun, F. Redini, and D. Heymann, “The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling,” Cytokine and Growth Factor Reviews, vol. 15, no. 6, pp. 457–475, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Yamaguchi, “Characterization of structural domains of human osteoclastogenesis inhibitory factor,” The Journal of Biological Chemistry, vol. 273, no. 9, pp. 5117–5123, 1998. View at Publisher · View at Google Scholar
  11. M. Baud'huin, L. Duplomb, S. Teletchea et al., “Osteoprotegerin: multiple partners for multiple functions,” Cytokine and Growth Factor Reviews, vol. 24, no. 5, pp. 401–409, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. H. L. Wright, H. S. McCarthy, J. Middleton, and M. J. Marshall, “RANK, RANKL and osteoprotegerin in bone biology and disease,” Current Reviews in Musculoskeletal Medicine, vol. 2, no. 1, pp. 56–64, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. B. F. Boyce and L. Xing, “Functions of RANKL/RANK/OPG in bone modeling and remodeling,” Archives of Biochemistry and Biophysics, vol. 473, no. 2, pp. 139–146, 2008. View at Publisher · View at Google Scholar
  14. M. Schoppet, M. M. Kavurma, L. C. Hofbauer, and C. M. Shanahan, “Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin,” Biochemical and Biophysical Research Communications, vol. 407, no. 1, pp. 103–107, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Lawrie, E. Waterman, M. Southwood et al., “Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension,” American Journal of Pathology, vol. 172, no. 1, pp. 256–265, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. C. W. Zannettino, C. A. Holding, P. Diamond et al., “Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor,” Journal of Cellular Physiology, vol. 204, no. 2, pp. 714–723, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. M.-E. Chollet, J.-P. Brouland, C. B. D. Sollier, F. Bauduer, L. Drouet, and S. Bellucci, “Evidence of a colocalisation of osteoprotegerin (OPG) with von Willebrand factor (VWF) in platelets and megakaryocytes alpha granules. Studies from normal and grey platelets,” British Journal of Haematology, vol. 148, no. 5, pp. 805–807, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Bitto, G. De Caridi, F. Polito et al., “Evidence for markers of hypoxia and apoptosis in explanted human carotid atherosclerotic plaques,” Journal of Vascular Surgery, vol. 52, no. 4, pp. 1015–1021, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Pérez de Ciriza, M. Moreno, P. Restituto et al., “Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification,” Clinical Biochemistry, vol. 47, no. 18, pp. 272–278, 2014. View at Publisher · View at Google Scholar
  20. A. C. Bharti, Y. Takada, S. Shishodia, and B. B. Aggarwal, “Evidence that receptor activator of Nuclear Factor (NF)-κB ligand can suppress cell Proliferation and induce apoptosis through activation of a NF-κB-independent and TRAF6-dependent mechanism,” The Journal of Biological Chemistry, vol. 279, no. 7, pp. 6065–6076, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Khosla, “Minireview: the OPG/RANKL/RANK system,” Endocrinology, vol. 142, no. 12, pp. 5050–5055, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Klejna, B. Naumnik, K. Gasowska, and M. Myśliwiec, “OPG/RANK/RANKL signaling system and its significance in nephrology,” Folia Histochemica et Cytobiologica, vol. 47, no. 2, pp. 199–206, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Van Campenhout and J. Golledge, “Osteoprotegerin, vascular calcification and atherosclerosis,” Atherosclerosis, vol. 204, no. 2, pp. 321–329, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Reid and I. Holen, “Pathophysiological roles of osteoprotegerin (OPG),” European Journal of Cell Biology, vol. 88, no. 1, pp. 1–17, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Malliga, D. Wagner, and A. Fahrleitner-Pammer, “The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology—a review,” Wiener Medizinische Wochenschrift, vol. 161, no. 23-24, pp. 565–570, 2011. View at Publisher · View at Google Scholar
  26. L. Nahidi, S. T. Leach, D. A. Lemberg, and A. S. Day, “Osteoprotegerin exerts its pro-inflammatory effects through nuclear factor-κb activation,” Digestive Diseases and Sciences, vol. 58, no. 11, pp. 3144–3155, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Vaccarezza, R. Bortul, R. Fadda, and M. Zweyer, “Increased OPG expression and impaired opg/trail ratio in the Aorta of diabetic rats,” Medicinal Chemistry, vol. 3, no. 4, pp. 387–391, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Augoulea, N. Vrachnis, I. Lambrinoudaki et al., “Osteoprotegerin as a marker of atherosclerosis in diabetic patients,” International Journal of Endocrinology, vol. 2013, Article ID 182060, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. G.-D. Xiang, H.-L. Sun, and L.-S. Zhao, “Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients,” Diabetes Research and Clinical Practice, vol. 76, no. 2, pp. 199–206, 2007. View at Publisher · View at Google Scholar
  30. D. K. Singh, P. Winocour, B. Summerhayes, A. Viljoen, G. Sivakumar, and K. Farrington, “Low serum osteoprotegerin levels in normoalbuminuric type 1 diabetes mellitus,” Acta Diabetologica, vol. 47, supplement 1, pp. S105–S110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. L. M. Rasmussen, L. Tarnow, T. K. Hansen, H.-H. Parving, and A. Flyvbjerg, “Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular mordibity in type 1 diabetic patients,” European Journal of Endocrinology, vol. 154, no. 1, pp. 75–81, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Grauslund, L. M. Rasmussen, A. Green, and A. K. Sjølie, “Does osteoprotegerin relate to micro- and macrovascular complications in long-term type 1 diabetes?” Scandinavian Journal of Clinical & Laboratory Investigation, vol. 70, no. 3, pp. 188–193, 2010. View at Publisher · View at Google Scholar
  33. S. T. Wang, J. M. Xu, M. Wang, F. L. Chen, and G. Ding, “Increased plasma osteoprotegerin concentrations in Type 1 diabetes with albuminuria,” Clinical Nephrology, vol. 79, pp. 192–198, 2013. View at Publisher · View at Google Scholar
  34. M. Nybo, M. K. Poulsen, J. Grauslund, J. E. Henriksen, and L. M. Rasmussen, “Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in type 1 and type 2 diabetic patients,” Diabetic Medicine, vol. 27, no. 3, pp. 289–294, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Gordin, A. Soro-Paavonen, M. C. Thomas et al., “Osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes,” Diabetes Care, vol. 36, no. 7, pp. 1827–1833, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Jorsal, L. Tarnow, A. Flyvbjerg, H.-H. Parving, P. Rossing, and L. M. Rasmussen, “Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy,” Diabetologia, vol. 51, no. 11, pp. 2100–2107, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Avignon, A. Sultan, C. Piot et al., “Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients,” Diabetes Care, vol. 30, no. 11, pp. 2934–2939, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. A. M. Blázquez-Medela, L. García-Ortiz, M. A. Gómez-Marcos et al., “Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes,” European Journal of Clinical Investigation, vol. 42, no. 5, pp. 548–556, 2012. View at Publisher · View at Google Scholar
  39. A. Gaudio, F. Privitera, I. Pulvirenti, E. Canzonieri, R. Rapisarda, and C. E. Fiore, “Relationships between osteoprotegerin, receptor activator of the nuclear factor κB ligand and serum levels and carotid intima-media thickness in patients with type 2 diabetes mellitus,” Panminerva Medica, vol. 56, pp. 221–225, 2014. View at Google Scholar
  40. S. Guzel, A. Seven, A. Kocaoglu et al., “Osteoprotegerin, leptin and IL-6: association with silent myocardial ischemia in type 2 diabetes mellitus,” Diabetes and Vascular Disease Research, vol. 10, no. 1, pp. 25–31, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Yaturu, J. Rains, and S. K. Jain, “Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-α levels in men with type 2 diabetes,” Cytokine, vol. 44, no. 1, pp. 168–171, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. E. P. O'Sullivan, D. T. Ashley, C. Davenport et al., “Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes,” Diabetes/Metabolism Research and Reviews, vol. 26, no. 6, pp. 496–502, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. Y.-H. Chang, K.-D. Lin, S.-R. He, M.-C. Hsieh, J.-Y. Hsiao, and S.-J. Shin, “Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy,” Metabolism: Clinical and Experimental, vol. 60, no. 8, pp. 1064–1069, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. H. M. Terekeci, M. G. Senol, C. Top et al., “Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy,” Experimental and Clinical Endocrinology and Diabetes, vol. 117, no. 3, pp. 119–123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. W. J. Y. Chen, L. J. Rijzewijk, R. W. van der Meer et al., “Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men,” Cardiovascular Diabetology, vol. 10, article 67, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. A. E. Altinova, F. Toruner, M. Akturk et al., “Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 71, no. 4, pp. 340–343, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Tavintharan, L. T. Pek, J. J. Liu et al., “Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus,” Diabetes & Vascular Disease Research, vol. 11, no. 5, pp. 359–362, 2014. View at Publisher · View at Google Scholar
  48. S. T. Knudsen, C. H. Foss, P. L. Poulsen, N. H. Andersen, C. E. Mogensen, and L. M. Rasmussen, “Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications,” European Journal of Endocrinology, vol. 149, no. 1, pp. 39–42, 2003. View at Publisher · View at Google Scholar
  49. G. Yu, X. Ji, J. Jin, and S. Bu, “Association of serum and vitreous concentrations of osteoprotegerin with diabetic retinopathy,” Annals of Clinical Biochemistry, vol. 52, pp. 232–236, 2015. View at Publisher · View at Google Scholar
  50. M. Ishiyama, E. Suzuki, J. Katsuda et al., “Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients,” Diabetes Research and Clinical Practice, vol. 85, no. 2, pp. 189–196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. P. R. Moreno, R. R. García, A. García-Martin, M. Varsavsky, J. A. García-Salcedo, and M. Muñoz-Torres, “Serum osteoprotegerin: Bone or cardiovascular marker in type 2 diabetes males?” Journal of Endocrinological Investigation, vol. 36, no. 1, pp. 16–20, 2013. View at Publisher · View at Google Scholar
  52. A. Ndip, F. L. Wilkinson, E. B. Jude, A. J. Boulton, and M. Y. Alexander, “RANKL–OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy,” Diabetologia, vol. 57, no. 11, pp. 2251–2260, 2014. View at Publisher · View at Google Scholar
  53. A. Aoki, M. Murata, T. Asano et al., “Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes,” Cardiovascular Diabetology, vol. 12, no. 1, article 11, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. D. K. Singh, P. Winocour, B. Summerhayes et al., “Prevalence and progression of peripheral vascular calcification in type 2 diabetes subjects with preserved kidney function,” Diabetes Research and Clinical Practice, vol. 97, no. 1, pp. 158–165, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. D. V. Anand, A. Lahiri, E. Lim, D. Hopkins, and R. Corder, “The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects,” Journal of the American College of Cardiology, vol. 47, no. 9, pp. 1850–1857, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. D. V. Anand, E. Lim, D. Darko et al., “Determinants of progression of coronary artery calcification in type 2 diabetes: role of glycemic control and inflammatory/vascular calcification markers,” Journal of the American College of Cardiology, vol. 50, no. 23, pp. 2218–2225, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. O. Bourron, C. E. Aubert, S. Liabeuf et al., “Below-knee arterial calcification in type 2 diabetes: association with receptor activator of nuclear factor κB ligand, osteoprotegerin, and neuropathy,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 11, pp. 4250–4258, 2014. View at Publisher · View at Google Scholar
  58. H. Reinhard, M. Nybo, P. R. Hansen et al., “Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria,” Cardiovascular Diabetology, vol. 10, article 70, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Avignon, A. Sultan, C. Piot, S. Elaerts, J. P. Cristol, and A. M. Dupuy, “Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients,” Diabetes Care, vol. 28, no. 9, pp. 2176–2180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. M. K. Poulsen, M. Nybo, J. Dahl et al., “Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus,” Cardiovascular Diabetology, vol. 10, article 76, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Reinhard, M. Lajer, M.-A. Gall et al., “Osteoprotegerin and mortality in type 2 diabetic patients,” Diabetes Care, vol. 33, no. 12, pp. 2561–2566, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. E. P. O'Sullivan, D. T. Ashley, C. Davenport et al., “A comparison of osteoprotegerin with adiponectin and high-sensitivity C-reactive protein (hsCRP) as a marker for insulin resistance,” Metabolism: Clinical and Experimental, vol. 62, no. 1, pp. 34–38, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. D. Hofsø, T. Ueland, H. Hager et al., “Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose,” European Journal of Endocrinology, vol. 161, no. 3, pp. 451–458, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. S. T. Knudsen, P. Jeppesen, P. L. Poulsen et al., “Plasma concentrations of osteoprotegerin during normo- and hyperglycaemic clamping,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 67, no. 2, pp. 135–142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Secchiero, F. Corallini, A. Pandolfi et al., “An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction,” American Journal of Pathology, vol. 169, no. 6, pp. 2236–2244, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. G. M. Jorgensen, B. Vind, M. Nybo, L. M. Rasmussen, and K. Hojlund, “Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity,” European Journal of Endocrinology, vol. 161, no. 1, pp. 95–101, 2009. View at Publisher · View at Google Scholar
  67. J. Suliburska, P. Bogdanski, E. Gajewska, G. Kalmus, M. Sobieska, and W. Samborski, “The association of insulin resistance with serum osteoprotegerin in obese adolescents,” Journal of Physiology and Biochemistry, vol. 69, no. 4, pp. 847–853, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. B. Ugur-Altun and A. Altun, “Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women,” Archives of Medical Research, vol. 38, no. 8, pp. 891–896, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. D. T. Ashley, E. P. O'Sullivan, C. Davenport et al., “Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects,” Metabolism: Clinical and Experimental, vol. 60, no. 7, pp. 994–1000, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. B. Ugur-Altun, A. Altun, M. Gerenli, and A. Tugrul, “The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity,” Diabetes Research and Clinical Practice, vol. 68, no. 3, pp. 217–222, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Holecki, B. Zahorska-Markiewicz, J. Janowska et al., “Osteoprotegerin-does it play a protective role in the pathogenesis of bone loss in obese perimenopausal women?” Endokrynologia Polska, vol. 58, no. 1, pp. 7–10, 2007. View at Google Scholar · View at Scopus
  72. A. A. Mahabadi, J. M. Massaro, G. A. Rosito et al., “Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study,” European Heart Journal, vol. 30, no. 7, pp. 850–856, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. M. C. Kühn, H. S. Willenberg, M. Schott et al., “Adipocyte-secreted factors increase osteoblast proliferation and the OPG/RANKL ratio to influence osteoclast formation,” Molecular and Cellular Endocrinology, vol. 349, no. 2, pp. 180–188, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. P. Ducy, “The role of osteocalcin in the endocrine cross-talk between bone remodelling and energy metabolism,” Diabetologia, vol. 54, no. 6, pp. 1291–1297, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. V. Schwetz, T. Pieber, and B. Obermayer-Pietsch, “Mechanisms in endocrinology: the endocrine role of the skeleton: background and clinical evidence,” European Journal of Endocrinology, vol. 166, pp. 959–967, 2012. View at Publisher · View at Google Scholar
  76. J. J. An, D. H. Han, D. M. Kim et al., “Expression and regulation of osteoprotegerin in adipose tissue,” Yonsei Medical Journal, vol. 48, no. 5, pp. 765–772, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. J. N. Fain, B. M. Tagele, P. Cheema, A. K. Madan, and D. S. Tichansky, “Release of 12 adipokines by adipose tissue, nonfat cells, and fat cells from obese women,” Obesity, vol. 18, no. 5, pp. 890–896, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. T. Harsløf, L. B. Husted, M. Carstens et al., “The expression and regulation of bone-acting cytokines in human peripheral adipose tissue in organ culture,” Hormone and Metabolic Research, vol. 43, no. 7, pp. 477–482, 2011. View at Publisher · View at Google Scholar
  79. E. Fuentes, F. Fuentes, G. Vilahur, L. Badimon, and I. Palomo, “Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome,” Mediators of Inflammation, vol. 2013, Article ID 136584, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. B. Akinci, T. Demir, A. Celtik et al., “Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational diabetes,” Diabetes Research and Clinical Practice, vol. 82, no. 2, pp. 172–178, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Akinci, A. Celtik, F. Yuksel et al., “Increased osteoprotegerin levels in women with previous gestational diabetes developing metabolic syndrome,” Diabetes Research and Clinical Practice, vol. 91, no. 1, pp. 26–31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. I. Nabipour, M. Kalantarhormozi, B. Larijani, M. Assadi, and Z. Sanjdideh, “Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women,” Metabolism, vol. 59, no. 5, pp. 742–747, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. D. Dallmeier, M. G. Larson, R. S. Vasan et al., “Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham Heart Study,” Diabetology and Metabolic Syndrome, vol. 4, article 28, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Bernardi, B. Fabris, M. Thomas et al., “Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes,” Molecular and Cellular Endocrinology, vol. 394, no. 1-2, pp. 13–20, 2014. View at Publisher · View at Google Scholar
  85. E. Stępień, E. Wypasek, K. Stopyra, M. Konieczyńska, M. Przybyło, and M. Pasowicz, “Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals,” Clinical Biochemistry, vol. 44, no. 10-11, pp. 826–831, 2011. View at Publisher · View at Google Scholar
  86. E. Stpień, D. Fedak, P. Klimeczek et al., “Osteoprotegerin, but not osteopontin, as a potential predictor of vascular calcification in normotensive subjects,” Hypertension Research, vol. 35, no. 5, pp. 531–538, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. C. J. Lee, J. H. Wang, M. L. Chen, C. F. Yang, Y. C. Chen, and B. G. Hsu, “Serum osteoprotegerin is associated with arterial stiffness assessed according to the cardio-ankle vascular index in hypertensive patients,” Journal of Atherosclerosis and Thrombosis, vol. 22, no. 3, pp. 304–312, 2015. View at Publisher · View at Google Scholar
  88. C. Guo, F. Hu, S. Zhang, Y. Wang, and H. Liu, “Association between osteoprotegerin gene polymorphisms and cardiovascular disease in type 2 diabetic patients,” Genetics and Molecular Biology, vol. 36, no. 2, pp. 177–182, 2013. View at Publisher · View at Google Scholar
  89. S. Mankoč Ramuš, T. Kumše, M. Globočnik Petrovič, D. Petrovič, and I. Cilenšek, “SNP rs2073618 of the psteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes,” BioMed Research International, vol. 2013, Article ID 364073, 6 pages, 2013. View at Publisher · View at Google Scholar
  90. P. Nehring, B. Mrozikiewicz-Rakowska, A. Sobczyk-Kopcioł et al., “Osteoprotegerin gene rs2073617 and rs3134069 polymorphisms in type 2 diabetes patients and sex-specific rs2073618 polymorphism as a risk factor for diabetic foot,” Polskie Archiwum Medycyny Wewnetrznej, vol. 123, no. 4, pp. 176–182, 2013. View at Google Scholar · View at Scopus
  91. J. Golledge, E. Biros, P. Clancy, M. Cooper, L. J. Palmer, and P. E. Norman, “A single-nucleotide polymorphism in the gene encoding osteoprotegerin is associated with diastolic blood pressure in older men,” American Journal of Hypertension, vol. 22, no. 11, pp. 1167–1170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. H. Brändström, P. Gerdhem, F. Stiger et al., “Single nucleotide polymorphisms in the human gene for osteoprotegerin are not related to bone mineral density or fracture in elderly women,” Calcified Tissue International, vol. 74, no. 1, pp. 18–24, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. H. Brändström, F. Stiger, T. Kahan et al., “A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA),” Blood Pressure, vol. 13, no. 3, pp. 152–157, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. G.-D. Xiang, L. Xu, L.-S. Zhao, L. Yue, and J. Hou, “The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes,” Diabetes, vol. 55, no. 7, pp. 2126–2131, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. J. S. Park, M. H. Cho, J. S. Nam et al., “Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus,” European Journal of Endocrinology, vol. 164, no. 1, pp. 69–74, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Nybo, S. R. Preil, H. F. Juhl et al., “Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients,” Basic and Clinical Pharmacology and Toxicology, vol. 109, no. 6, pp. 481–485, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. B. Nellemann, L. C. Gormsen, J. Dollerup et al., “Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria,” Diabetes Care, vol. 30, no. 12, pp. 3122–3124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. K. Mori, S. Jono, M. Emoto et al., “Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes,” Angiology, vol. 61, no. 1, pp. 86–91, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. N. Nezami, J. Safa, A. T. Eftekhar-Sadat et al., “Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy,” Clinical Biochemistry, vol. 43, no. 16-17, pp. 1294–1299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. N. P. E. Kadoglou, G. Kottas, S. Lampropoulos, I. Vitta, and C. D. Liapis, “Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-reductase inhibitor) therapy,” Clinical Drug Investigation, vol. 34, no. 3, pp. 165–171, 2014. View at Publisher · View at Google Scholar · View at Scopus
  101. P. P. Dimitrow, M. Jawień, and A. Gackowski, “The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis,” Journal of Heart Valve Disease, vol. 20, no. 1, pp. 18–22, 2011. View at Google Scholar · View at Scopus
  102. H. Uzui, T. Morishita, A. Nakano et al., “Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 19, no. 3, pp. 304–309, 2014. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Holecki, B. Zahorska-Markiewicz, J. Janowska et al., “The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women,” Obesity, vol. 15, no. 8, pp. 1925–1929, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. M.-H. Gannagé-Yared, C. Yaghi, B. Habre et al., “Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study,” European Journal of Endocrinology, vol. 158, no. 3, pp. 353–359, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. C. Davenport, H. Kenny, D. T. Ashley, E. P. O'Sullivan, D. Smith, and D. J. O'Gorman, “The effect of exercise on osteoprotegerin and TNF-related apoptosis-inducing ligand in obese patients,” European Journal of Clinical Investigation, vol. 42, no. 11, pp. 1173–1179, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. P. Collin-Osdoby, L. Rothe, F. Anderson, M. Nelson, W. Maloney, and P. Osdoby, “Receptor activator of NF-κb and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis,” Journal of Biological Chemistry, vol. 276, no. 23, pp. 20659–20672, 2001. View at Publisher · View at Google Scholar · View at Scopus
  107. J. S. McGonigle, C. M. Giachelli, and M. Scatena, “Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function,” Angiogenesis, vol. 12, no. 1, pp. 35–46, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. S. H. Mangan, A. van Campenhout, C. Rush, and J. Golledge, “Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-α associated with induction of angiopoietin-2,” Cardiovascular Research, vol. 76, no. 3, pp. 494–505, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. G. Zauli, F. Corallini, F. Bossi et al., “Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo,” Blood, vol. 110, no. 2, pp. 536–543, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. M.-F. Heymann, F. Herisson, J.-M. Davaine et al., “Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds,” Cytokine, vol. 58, no. 2, pp. 300–306, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. B. Toffoli, R. J. Pickering, D. Tsorotes et al., “Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop,” Atherosclerosis, vol. 218, no. 1, pp. 61–68, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. A. Callegari, M. L. Coons, J. L. Ricks, M. E. Rosenfeld, and M. Scatena, “Increased calcification in osteoprotegerin-deficient smooth muscle cells: dependence on receptor activator of NF-κB Ligand and Interleukin 6,” Journal of Vascular Research, vol. 51, no. 2, pp. 118–131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. R. Candido, B. Toffoli, F. Corallini et al., “Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo,” Journal of Vascular Research, vol. 47, no. 3, pp. 252–261, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. S. Morony, Y. Tintut, Z. Zhang et al., “Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice,” Circulation, vol. 117, no. 3, pp. 411–420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. K. Caidahl, T. Ueland, and P. Aukrust, “Osteoprotegerin: a biomarker with many faces,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 9, pp. 1684–1686, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. P. Clancy, L. Oliver, R. Jayalath, P. Buttner, and J. Golledge, “Assessment of a serum assay for quantification of abdominal aortic calcification,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 11, pp. 2574–2576, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. K. E. Naylor, A. Rogers, R. B. Fraser, V. Hall, R. Eastell, and A. Blumsohn, “Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 11, pp. 5361–5365, 2003. View at Publisher · View at Google Scholar · View at Scopus
  118. C. Pérez de Ciriza, A. Lawrie, and N. Varo, “Influence of pre-analytical and analytical factors on osteoprotegerin measurements,” Clinical Biochemistry, vol. 47, no. 13-14, pp. 1279–1285, 2014. View at Publisher · View at Google Scholar
  119. B. Y. Y. Chan, K. A. Buckley, B. H. Durham, J. A. Gallagher, and W. D. Fraser, “Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-κB ligand and osteoprotegerin in plasma and serum,” Clinical Chemistry, vol. 49, no. 12, pp. 2083–2085, 2003. View at Publisher · View at Google Scholar · View at Scopus
  120. M. Bjerre, “Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications,” SpringerPlus, vol. 2, article 658, 2013. View at Publisher · View at Google Scholar
  121. H. P. Sennels, S. Jacobsen, T. Jensen et al., “Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein,” Scandinavian Journal of Clinical & Laboratory Investigation, vol. 67, no. 8, pp. 821–835, 2007. View at Publisher · View at Google Scholar